Výsledky vyhledávání - "V A, Potashova"

[Treatment of patients with destructive pulmonary tuberculosis and nonspecific purulent endobronchitis]

Autor: G V, Pletnev, V A, Krasnov, V A, Potashova

Publikováno v: Problemy tuberkuleza. (2)

Imozymase treatment should be started from the first hospital days in patients with destructive pulmonary tuberculosis concurrent with nonspecific purulent endobronchitis. Two-week ultrasound inhalations with imozymase in a dose of 1 ml (60 PU) may r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dc673cd630bcd5df4accef2594102244
https://pubmed.ncbi.nlm.nih.gov/12790031

Zobrazit plný text záznamu

[Modalities of complex therapy in different categories of patients with pulmonary tuberculosis]

Autor: V A, Krasnov, V A, Potashova, S L, Naryshkina, O A, Kudelia

Publikováno v: Problemy tuberkuleza. (2)

The paper proposes the standards of combined treatment involving intermittent intravenous bactericidal chemotherapy for different groups of patients. It describes treatment regimens at the inpatient stage, defines the scope and time of control examin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b2c1a0d53283de8a7041673daaed9755
https://pubmed.ncbi.nlm.nih.gov/12790029

Zobrazit plný text záznamu

[On early transfer of new cases of pulmonary tuberculosis to outpatient treatment]

Autor: I G, Ursov, V A, Krasnov, T A, Borovinskaia, V A, Potashova, S L, Naryshkina, E G, Ron'zhina, T I, Petrenko

Publikováno v: Problemy tuberkuleza. (2)

Based on 228 clinical cases, the authors propose procedures for complex two-stage (inpatient and outpatient) treatments of new cases of pulmonary tuberculosis by using intermittent intravenous chemotherapy that makes it possible to have a high therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::668ceee023fe4b169fc4a04cd4dc6601
https://pubmed.ncbi.nlm.nih.gov/12790028

Zobrazit plný text záznamu

[Possibilities of the use of immobilized proteolytic enzyme immozymase in tuberculosis]

Autor: V A, Krasnov, N N, Kozhevnikov, V E, Beliavskiĭ, V A, Potashova, A A, Andrenko, E V, Kul'chavenia, S L, Naryshkina, A V, Svistel'nik, N G, Grishchenko, V T, Khomiakov

Publikováno v: Problemy tuberkuleza. (3)

The paper summarises the experience gained in the use of immozymase in tuberculous patients to advance the disease diagnosis and treatment. Immozymase proved valuable in obtaining sputum enriched with M. tuberculosis in patients who were previously c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cacab9d8cdabf8684d022908befb08e1
https://pubmed.ncbi.nlm.nih.gov/7617627

Zobrazit plný text záznamu

[Clinical aspects and outcome of recurrent pulmonary tuberculosis]

Autor: V A, Krasnov, V A, Potashova, T V, Zyrianova, S L, Naryshkina

Publikováno v: Problemy tuberkuleza. (5)

Recurrent tuberculosis was treated in hospital in 86 patients, 82.7% of whom had destructive disease, while 84.0% disseminated the bacteria. Combined chemotherapy included 4 tuberculostatic drugs: 10% isoniazid (7 mg/kg iv drip), streptomycin (0.5 g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::31ae56b92177b6d2bc40e89c3eedc7b8
https://pubmed.ncbi.nlm.nih.gov/8295875

Zobrazit plný text záznamu

[The organization and efficacy of the hospital treatment of patients with newly detected pulmonary tuberculosis in Siberia]

Autor: V A, Krasnov, V A, Potashova

Publikováno v: Problemy tuberkuleza. (11-12)

Analysis of the clinical observations of 2049 patients with newly diagnosed pulmonary tuberculosis has demonstrated that 54.3% of them had the destructive phase, 52.2% bacilli excretion, 20.7% the neglected forms, and 64.3% attendant diseases. The ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::85b15d0460381abe0e50ff4f1daf7818
https://pubmed.ncbi.nlm.nih.gov/1289878

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání